16937105

Source:http://linkedlifedata.com/resource/pubmed/id/16937105

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0069717, umls-concept:C0087111, umls-concept:C0206754, umls-concept:C0671970, umls-concept:C1956962
pubmed:issue	5
pubmed:dateCreated	2007-2-19
pubmed:abstractText	The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours' (NETs) treatment.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Chromogranin A, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0344-5704
pubmed:author	pubmed-author:BajettaEmilioE, pubmed-author:BajettaRobertoR, pubmed-author:BichisaoEttoreE, pubmed-author:CatenaLauraL, pubmed-author:De DossoSaraS, pubmed-author:FerrariLeonardoL, pubmed-author:FormisanoBarbaraB, pubmed-author:MartinettiAntoniaA, pubmed-author:PlataniaMarcoM, pubmed-author:ProcopioGiuseppeG, pubmed-author:VerzoniElenaE
pubmed:issnType	Print
pubmed:volume	59
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	637-42
pubmed:meshHeading	pubmed-meshheading:16937105-Adult, pubmed-meshheading:16937105-Aged, pubmed-meshheading:16937105-Aged, 80 and over, pubmed-meshheading:16937105-Antimetabolites, Antineoplastic, pubmed-meshheading:16937105-Antineoplastic Agents, pubmed-meshheading:16937105-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16937105-Chromogranin A, pubmed-meshheading:16937105-Deoxycytidine, pubmed-meshheading:16937105-Disease Progression, pubmed-meshheading:16937105-Drug Combinations, pubmed-meshheading:16937105-Female, pubmed-meshheading:16937105-Fluorouracil, pubmed-meshheading:16937105-Humans, pubmed-meshheading:16937105-Male, pubmed-meshheading:16937105-Middle Aged, pubmed-meshheading:16937105-Neuroendocrine Tumors, pubmed-meshheading:16937105-Organoplatinum Compounds, pubmed-meshheading:16937105-Survival Analysis, pubmed-meshheading:16937105-Tumor Markers, Biological
pubmed:year	2007
pubmed:articleTitle	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
pubmed:affiliation	S.C. Oncologia Medica 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian, 1, Milan 20133, Italy. emilio.bajetta@istitutotumori.mi.it
pubmed:publicationType	Journal Article